Pharmacyclics Announces Presentation of Results From Phase I Trial of Its First-in-Human Btk Inhibitor: PCI-32765

Sunday, June 6, 2010 General News
Email Print This Page Comment bookmark
Font : A-A+

N

Complete Response

Partial Response

Stable Disease

Progressive Disease

Not Evaluable*

Evaluable

RR%

ORR %

ITT**

Chronic/Small  Lymphocytic Leukemia (CLL/SLL)

13

1

8

2

0

2

82%

(9/11)

69%

(9/13)

Mantle Cell (MCL)

4

1

2

1

0

75%

(3/4)

75%

(3/4)

Diffuse Large B Cell Lymphoma (DLBCL)

6

1

1

4

17%

(1/6)

17%

(1/6)

Follicular Lymphoma (FL)

13

3

4

4

2

27%

(3/11)

23%

(3/13)

Marginal

4

1

1

1

1

33%

(1/3)

25%

(1/4)

Total

40

2

15

9

9

5

49%

(17/35)

43%

(17/40)

* Includes those patients who did not complete 2 cycles of therapy and withdrew from study

** Includes all “Intent To Treat” patients



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook